Analysis of Pharmaceutical Residual Solvents Using Comprehensive Two-Dimensional Gas Chromatograhy - - Chromatography Online
FindAnalytichem Custom Search
About Search
Analysis of Pharmaceutical Residual Solvents Using Comprehensive Two-Dimensional Gas Chromatograhy


LCGC North America




Analysis of the solvents involved in the manufacturing process is a longstanding regulatory requirement in the pharmaceutical industry. According to the initial guidelines proposed by the International Conference on Harmonization (ICH) and by the United States Pharmacopeia (USP, General Chapter <467>) and European Pharmacopeia (EP), manufacturing solvents must be carefully regulated because they have varying levels of toxicity or environmental hazard and they have no therapeutic benefit (1–3). The solvents are grouped into three classes:

Class 1: Solvents to be avoided because they are highly toxic or are especially hazardous to the environment. Required daily exposure limits are 2–1500 ppm.

Class 2: Solvents with moderate toxicity, including most common solvents used in synthetic processes. Required daily exposure limits are 20–4800 ppm.

Class 3: Solvents with little or no toxicity. Required daily exposure limit of 5000 ppm. If only class 3 solvents are present, they can be quantified by loss on drying, with quantitation by gas chromatography (GC) if the level exceeds 5000 ppm.


Table I: USP and ICH Class 1, 2, and 3 solvents with first and second dimension retention times and concentration limits
There is also a fourth class of solvents for which there is not sufficient toxicological data to establish a requirement. The class 1, 2, and 3 solvents and their maximum exposure limits are shown in Table I along with their comprehensive two-dimensional GC (GC×GC) retention times using the separation conditions described in this article. Maximum daily exposure (MDE) is used to determine the required concentration limit for an individual method. In United States Pharmacopeia (USP) method <467>, Residual Solvents, the required concentration limit is determined from the MDE based upon a daily dosage of 10 g of the final drug product (4). If the dosage is less than 10 g, the allowable detection limit in a method would be higher; if the dosage is more than 10 g, the allowable detection limit is lower.

Table I demonstrates the two challenges in developing a single comprehensive GC method for pharmaceutical solvents: there are about 60 compounds in classes 1–3 and the allowable concentration limits can range over three orders of magnitude (2–5000 ppm for a 10-g dose of the drug) within the same sample. While there has been considerable work and there are numerous residual solvents methods reported in the literature, a single comprehensive method encompassing both challenges in one run does not currently exist (5–9). Most methods were designed for individual problems and involve the separation of 3–10 solvents with run times of 10–30 min or more. The large number of compounds coupled with their varying chemistry necessitates the use of separations run on multiple columns of differing selectivity methods if a single method to separate all of them in a reasonable amount of time, as described in USP <467>, is desired.


ADVERTISEMENT

post a comment
Your email address will NOT be published.
appears with your comment
read our privacy policy
Note: does not support HTML
All Comments submitted are subject to review, and may be delayed before posting. Comments will be posted at the discretion of the editor.
LCGC E-mail Newsletters
Select each newsletter you wish to subscribe for:
| Monthly
| Weekly
| Monthly
 Name:
 E-mail:
more info
Survey
What was your primary reason for attending HPLC 2009?
Education — furthering knowledge by attending lectures
Attending exhibition
Exhibiting at the show
A combination of all three
Other
Education — furthering knowledge by attending lectures
0%
Attending exhibition
0%
Exhibiting at the show
67%
A combination of all three
0%
Other
33%
View Results
Tell us more about what you thought of HPLC in our LinkedIn group
Source: LCGC North America,
Click here